Background: This study aimed to examine the quality in oncology registration trials for new drug application (NDA) or supplemental new drug application (sNDA) as extensions of the indications for use in Japan based on Good Clinical Practice (GCP) audit findings. Results: Among the 40 audits for oncology drug applications, the frequencies at which one or more deficiencies ascribed to institution, investigator, sponsor, and institutional review board were found to be 15 (37.5%), 13 (32.5%), 21 (52.5%), and 10 (25.0%), respectively. The exclusion of patients from the review objective due to serious violations of GCP in 40 audits for oncology drug applications was observed in 2 (5.0%) cases, whereas that in the remaining 343 audits for other drug applications was observed in 40 (11.7%) cases.
introduction
Approval of new drug applications (NDA) or supplemental new drug applications (sNDA) for extension of the range of indication and/or posology as well as the method of administration is based on collecting evidential materials from registration trials that are strictly managed in terms of quality control and quality assurance. The registration trials for applications are conducted in conformity with Good Clinical Practice (GCP) that provides corroboration of both ethics and science. The purpose of GCP is to protect the human rights and safety of the subjects and is based on the World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subject in order to ensure accurate data and reliability in registration trials [1] . The Ministry of Health and Welfare [currently Ministry of Health, Labour and Welfare (MHLW)] of Japan had issued instructions regarding the old GCP guideline in October 1990, which was not legally binding [2] . In April 1997, a new GCP guideline was enforced in response to the implementation of the GCP released by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use for all Japanese registration trials that began from April 1998 onward [3, 4] . Major differences between the old and new GCP guidelines are related to the acquisition of written informed consent documents, intensification of the responsibility of the sponsor, clarification of the responsibility and role of the principal investigator, and improvements in the function of the institutional review board (IRB) and supports for registration trials [2, 3] .
In Japan, the number of clinical trial protocol notifications for oncology drug applications is rapidly increasing with each passing year; oncology drug applications comprised 15% of all clinical trial protocol notifications in the fiscal year 2007 [5] . The number of clinical trial protocol notifications among global registration trials has been increasing substantially; moreover, clinical trial protocol notifications for oncology drugs comprised 59% of global clinical trial protocol notifications, making it the largest field in drug applications in the fiscal year 2007 [6] . It appears that clinical development in the oncology drug field became both active and stable in Japan around this time. These conditions have also made it easier to carry oncology registration trials with sufficient quality according to GCP as compared with that in other drug fields.
Clinical In this study, we examined GCP compliance in oncology registration trials in order to ensure high-quality clinical trials in Japan. The GCP compliance of the registration trials for NDA and sNDA was examined based on the Pharmaceuticals and Medical Devices Agency's (PMDA) judgment on recent overall results of on-site GCP audits. We have discussed the quality of oncology registration trials through a comparison of the deficiencies found in GCP inspections that were ascribed to the institution, investigator, sponsor, and IRB between 40 oncology drugs applications and 343 drug applications for other diseases.
materials and methods

GCP inspection of PMDA in Japan
The Office of Conformity Audit of PMDA carried out GCP inspections that consisted of document-based conformity audit at the PMDA along with on-site GCP audits [7] . The document-based conformity audit exhaustively inspects the consistency between application materials attached to the application form for approval and all evidential materials of all institutions retained by study sponsors (e.g. case report forms, monitoring records, etc.) from the viewpoint of Good Laboratory Practice, GCP, and conformity criteria of the application materials. The on-site GCP audit inspects the consistency between raw data (e.g. medical records, examination slips, and patient diaries) as evidential materials of surveyed medical institutions and evidential documents of surveyed institutions held by study sponsors (e.g., case report forms). In addition, the on-site GCP audit inspects the general institutional structure for registration trials at the institution (e.g. administration of the medical institution, IRB, maintenance of essential archives, and investigational drug accountability of the pharmacy). The objectives of on-site GCP audits in trial applications have been previously defined [8] . On-site GCP audits are generally carried out for four institutions in NDA and two institutions in sNDA. An institution in Japan or another country enrolling many patients into a pivotal registration trial of application is selected for on-site GCP audit. The PMDA finally judges GCP compliance as follows: conformation, conformation with proviso, or nonconformation. The results are sent to both the sponsor and the institution.
Conformation indicates complete compliance with the GCP in the registration trial for the application. Conformation with proviso means that the PMDA imposes the exclusion of patients from the review objective due to serious violations of the GCP and evaluates the registration trial comprising the remaining patients. If a critical GCP violation concerning ethics and/or science in the registration trial is found, the PMDA judges that all the materials in the registration trial related to GCP nonconformation should be deleted from the application for NDA or sNDA. In this case, the PMDA generally concludes in favor of rejection of the application. It should be noted that when the PMDA's judgment is nonconformation, these results are not publicly released; therefore, the frequency of nonconformations is not investigated.
data sources
In Japan, for each application, on-site GCP inspection for the registration trials-including trials conducted in Japan and overseas for the drugs-are conducted, and their comprehensive audit results are publicly released with exposures of the deficiencies found in GCP inspections that are ascribed to the institution, investigator, sponsor, and IRB [9] . In this study, 344 audits, which were reviewed by the PMDA and approved by the MHLW of Japan between April 2004 and March 2010 (fiscal years 2004 to 2009), were examined, excluding public domain approvals and audits without on-site GCP inspections [10] . For each audit, the following data were collected: medicinal classification of the approved drug, approval year, the PMDA's judgment on GCP compliance (conformation with/without proviso), the number of patients excluded due to serious violations of GCP, GCP deficiencies, and responsible participants of deficiencies (institution, investigator, sponsor, and IRB).
Fisher's exact test was used to compare the frequency distributions with respect to the deficiencies between the audits for anticancer drugs and those for other diseases. A two-sided P £ 0.05 was considered to be statistically significant. All the analyses were carried out using the SAS software (version 9.1; SAS Institute Inc., Cary, NC).
results conformation with/without proviso
The approval years and medicinal classifications for 383 audits are shown in Table 1 . The audits for oncology drug applications comprised 40 (10.4%) of the 383 audits. Table 2 shows the proportions of conformation with/without proviso overall and for each medicinal classification. Overall, 89.6% of conformation and 10.4% of conformation with proviso were observed. Among the 42 audits judged as conformation with proviso, the frequencies of audits with ‡1 deficiencies ascribed to the institution, investigator, IRB, and sponsor were 34 (81.0%), 23 (54.8%), 12 (28.6%), and 25 (59.5%), respectively. Additionally, the frequencies of audits in each deficiency ascribed to each responsible participant are shown in Table 3 .
Conformation with proviso in 40 audits for anticancer drug applications were observed in 2 (5.0%) cases, whereas that in the remaining 343 audits for the other disease applications was observed in 40 (11.7%) (P = 0.286). The proportion of conformation with proviso in cancer registration trials tended to be smaller than that in the registration trials for other disease applications, although the number of audits varied depending upon the medicinal classification. Furthermore, although the number of excluded patients was unknown in 9 audits, among the 42 audits judged as conformation with proviso, the median number of excluded patients was 3 (range 1-182) in the remaining 33 audits.
responsible participants due to deficiencies Table 4 shows the distributions of audits in which one or more deficiencies were ascribed to the responsible participants overall and in each medicinal classification. The proportion of approvals with ‡1 deficiencies ascribed to the institution, investigator, IRB, and sponsor were 15 (37.5%), 13 (32.5%), 10 (25.0%), and 21 (52.5%) in 40 audits, respectively, for oncology drug applications and 168 (49.0%), 145 (42.3%), 78 (22.7%), and 169 (49.3%), respectively, in the remaining 343 audits for other drug applications. The deficiencies ascribed to the institution and investigator in the cancer registration trials tended to be lesser than those in the registration trials for other diseases (P = 0.184 for institution and P = 0.309 for investigator).
deficiencies ascribed to responsible participants Table 5 shows the frequencies of audits in each deficiency ascribed to each responsible participant overall and in each medicinal classification. The deficiencies related to archives, eligibility criteria, and prohibited concomitant therapies in 40 audits for oncology drug applications were 1 (2.5%), 2 (5.0%), and 0 (0.0%), respectively, whereas those in the 308 other drug audits were 47 (13.7%), 43 (12.5%), and 28 (8.2%), respectively (P = 0.043 for archives, P = 0.201 for eligibility criteria, and P = 0.099 for prohibited concomitant therapies). On the other hand, the deficiency of 'insufficient review' by the IRB in 40 audits for oncology drug applications was higher than that in the 343 other drug audits (17.5% versus 5.5%, P = 0.012).
discussion
The results of the present study indicated that the overall compliance of GCP in oncology registration trials was passably better than that in registration trials for other diseases, although there was no statistically significant difference between them. According to Table 5 , the problems related to archives in institutions were lesser but insufficient reviews by the IRB were more frequent in the oncology drug applications when compared with those for other diseases. Therefore, completeness of IRB reviews would enhance quality of drug applications in the oncology field.
Previous studies have analyzed a number of GCP deficiencies in registration trials for NDA or sNDA, approved by the MHLW of Japan, from the fiscal year 1997 to 2006 [11] [12] [13] [14] [15] [16] [17] [18] . Since a white paper or annual report regarding the overall results of on-site GCP audit has not been officially published, these studies have repeatedly used the same data that were partly released by the PMDA, workshops, or symposiums. In addition, most of these studies examined GCP deficiencies immediately after the enforcement of the new GCP guidelines [11] [12] [13] [14] [15] . The examination of compliance with GCP in registration trials for NDA or sNDA in recent times is required.
Our study demonstrated 10.4% of conformations with proviso in registration trials overall in the past 5 years. Previous studies have reported that conformations with proviso comprised 17.6% of registration trials during the fiscal years 2001 and 2003 [16] . Based on the results of the present study and those of previous studies, compliance with GCP in Japanese registration trials has generally been improving [16, 17] . Furthermore, the present study revealed the overall GCP compliance of oncology registration trials tended to be better than that of registration trials for other drugs.
The present study revealed trial institution deviations, investigator deviations, and sponsor deviations in 40%-50% of the audits. The frequencies of deviations related to the trial institution or investigator were lower in the oncology registration trials as compared with those in the other drug registration trials. This may be because the development of oncology drugs is highly specialized; therefore, research sources-including the trial institution, investigator, and other health care professionals-for the registration trials of oncology drugs have much greater experience and can carry registration trials with greater compliance. 
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Drug development generally takes considerably long due to the on-site GCP audit in response to a trial application. However, problems related to archives would essentially relate to the reliability of the registration trial regarding the existing subjects, ethics, and science. We noted no problems related to archives in the oncology drug registration trials; the frequency of this deficiency was clearly lower for oncology drugs as compared with other drugs. Thus, the compliance with GCP regarding archives was satisfactory in oncology drug registration trials.
The frequency of protocol deviation in oncology fields is lower than that for other medicinal classifications; however, protocol deviations for eligibility criteria or use of prohibited concomitant therapies would influence subject safety in registration trials. Therefore, investigators, clinical research coordinators (CRC), and other health care professionals who support registration trials should make an effort to have sufficient knowledge regarding the target disease and treatment and keep track of details regarding the protocol and GCP. The incidence of deficiencies at domestic investigational sites with CRC was 21% (N = 270/1260), which was lower than that of deficiencies at domestic investigational sites without CRC, i.e. 58% (N = 188/325) [7, 18] . Therefore, an effective approach for reducing deficiencies associated with protocol deviation would entail the careful selection of trial institutions with sufficient numbers of well-trained CRCs and suitable conditions for carrying out monitoring.
In the present study, deficiencies in monitoring were most frequent both overall and in sponsor deviations. Monitoring of the medical institution by the sponsor is enforced by GCP in order to ensure appropriate operation of the registration trial according to trial protocol and GCP. A previous study indicated that typical monitoring issues associated with sponsors in the fiscal year 2005 were as follows: operation of monitoring associated with standard operation procedure and source document verification (41%), timing of monitoring (9.5%), taking appropriate precautions to prevent deviation by monitoring report (8.5%), submission of monitoring report (5.5%), and other (35.5%) [18] . Appropriate monitoring for registration trial by a monitor who has been specifically trained and possesses scientific and clinical knowledge is important for ensuring quality control and quality assurance of registration trials. For further improvement in reducing deficiencies in monitoring, the monitor in the sponsor organization or contract research organization (CRO) should be sufficiently familiar with the protocol and GCP. Improved performance of various parties in the registration trial would not only facilitate operation of the registration trial by the sponsor but also the operation of investigator-initiated registration-directed clinical trials by the investigator, according to the revised GCP enforced from July 2003 [19] .
Another major item of deficiency related to the sponsor is a delay in communicating information regarding adverse drug reactions; this is related to subject safety, ethics, and operation of the registration trial. A seamless communication system for delivering critical information is important for ensuring subject safety and appropriate operation of the registration trial. In [20] . Furthermore, the MHLW science research grants 'research on clinical trials infrastructure development' were inaugurated to support framework development for promoting clinical trials (comprising grants to 10 leading academic medical centers). Thus, a study on 'the development of individual health care institution infrastructure models aimed at equally sharing cancer research infrastructure development' was started, and it became possible to pursue favorable institutional infrastructure development and human resources training concerning the ethical aspects of clinical research and methods of new drug development in the National Cancer Center Hospital [21, 22] . Furthermore, the Japanese Ministry of Education, Culture, Sports, Science and Technology provided grants to five universities and a clinical research organization named 'Coordination, Support and Training Program for Translational Research' in 2007 and onward [22, 23] . These various approaches promoted the establishment of a clinical trial infrastructure; we believe that an adequate infrastructure would be the optimal influence for ensuring compliance with GCP in registration trials.
Our study had certain limitations. We were not able to use the full data of on-site GCP audits for a number of trial institutions-such as the trial institution background, i.e. scale (university hospital, national hospital, private hospital, and clinic), region (Japan or other countries), number of subjects under on-site GCP audit, presence of supporting system for registered trial (CRC, site management organization, CRO, etc.)-because the PMDA review reports for on-site GCP audit are the only available data source and these do not have detailed data. Therefore, it is difficult to directly compare the results of the present study with those of previous studies. Because there 
